adebelimumab + famitinib + FOLFIRI + Ariely

This is a combination regimen consisting of four components: - **Adebelimumab** (presumed to be a monoclonal antibody; no publicly available data as of June 2025) - **Famitinib** (a small molecule tyrosine kinase inhibitor targeting VEGFR2 and other kinases) - **FOLFIRI**, a well-established chemotherapy regimen composed of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. FOLFIRI is used primarily for metastatic colorectal cancer and other gastrointestinal cancers. Folinic acid enhances the effect of 5-FU, which disrupts DNA synthesis in rapidly dividing cells. Irinotecan inhibits topoisomerase I, preventing DNA replication[1][2][4][5]. - **Ariely** (no information found; may be an investigational or misspelled agent) The combination appears to represent an experimental or hypothetical multi-drug oncology regimen combining immunotherapy/targeted therapy with cytotoxic chemotherapy.